RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Correlates of adherence to the dapivirine vaginal ring for HIV-1 prevention
Husnik, M. J., Brown, E. R., Dadabhai, S. S., Gaffoor, Z., Jeenarain, N., Kiweewa, F. M., Livant, E., Mansoor, L. E., Mirembe, B. G., Palanee-Phillips, T., Singh, D., Siva, S., Soto-Torres, L., van der Straten, A., Baeten, J. M., & M. T. N.-020/ASPIRE Study Team (2021). Correlates of adherence to the dapivirine vaginal ring for HIV-1 prevention. AIDS and Behavior, 25(9), 2801-2814. https://doi.org/10.1007/s10461-021-03231-x
Understanding characteristics associated with adherence to pre-exposure prophylaxis (PrEP) methods for HIV-1 prevention may assist with optimizing implementation efforts. The dapivirine vaginal ring is a novel topical PrEP delivery method. Using data from a randomized, double-blind, placebo-controlled, phase III trial of the dapivirine vaginal ring conducted in four African countries, generalized estimating equation models were used to evaluate correlates of ring adherence. Two levels of quarterly dapivirine blood plasma, and dapivirine released from returned rings defined measures of adherence for recent and cumulative use, respectively. Time on study, calendar time, primary partner knowledge that the participant was taking part in the study, and use of long-acting contraceptive methods were associated with ring adherence whereas younger age, ring worries, condom use, episodes of menstrual bleeding and vaginal washing were associated with non-adherence. These findings may be useful for recruitment into future clinical studies and dapivirine ring implementation efforts.